A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

ABSTRACT: Primary therapy resistance is a major problem in acute myeloid leukemia treatment. We set out to develop a powerful and robust predictor for therapy resistance for intensively treated adult patients. We used two large gene expression data sets (n=856) to develop a predictor of therapy resistance, which was validated in an independent cohort analyzed by RNA sequencing (n=250). In addition to gene expression markers, standard clinical and laboratory variables as well as the mutation status of 68 genes were considered during construction of the model. The final predictor (PS29MRC) consisted of 29 gene expression markers and a cytogenetic risk classification. A continuous predictor is calculated as a weighted linear sum of the individual variables. In addition, a cut off was defined to divide

SUBMITTER: Herold T 

PROVIDER: S-EPMC5830382 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature